CFO — Lisa Wolf: The voluntary resignation of the President, COO, and CFO is a significant loss of senior management with no immediate successor named.

General Counsel — Melinda Lackey: The filing discloses the termination of the General Counsel and Senior Vice President of Legal Affairs, representing the loss of a senior officer.

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. Series B Closing Valion Bio, Inc., a Delaware corporation (the “Company”), and 3i, LP (“3i”) are party to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the purchase and sale of (a) up to 8,400 shares of the Company’s Series B Non-Voting Convertible Preferred Stock (“Series B Preferred Shares”) and (b) warrants (“Ser…

Entry into a Material Definitive Agreement. Valion Bio, Inc., a Delaware corporation (the “Company”), and 3i, LP (“3i”) are parties to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the purchase and sale of (a) up to 8,400 shares of the Company’s Series B Non-Voting Convertible Preferred Stock (“Series B Preferred Shares”) and (b) warrants (“Series B Warrants”…

Unregistered Sales of Equity Securities. The information contained in

CEO — Dean Zikria: A sitting board member was appointed as Interim CEO, representing an internal succession rather than a departure of an existing executive.

Director — Jared Malbin: The filing discloses the appointment of two new directors to the board, which is a routine governance event and not a departure of an executive.

Entry into a Material Definitive Agreement. Valion Bio, Inc., a Delaware corporation (the “Company”) and 3i, LP (“3i”) are parties to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the purchase and sale of (a) up to 8,400 shares of the Company’s Series B Non-Voting Convertible Preferred Stock (“Series B Preferred Shares”) and (b) warrants (“Series B Warrants”)…

Unregistered Sales of Equity Securities. The information contained in

Material Modification to Rights of Security Holders. To the extent required by

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement The Company and 3i, LP (“3i”) are parties to that certain Securities Purchase Agreement, dated April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the purchase and sale of up to 8,400 shares of the Company’s Series B Non-Voting Convertible Preferred Stock (“Series B Preferred Shares”) and warrants (“Series B Warrants”) to purchase shares of the Company’s common stock for an agg…

CEO — Michael K. Handley: The CEO was terminated effective immediately, which constitutes a sudden executive departure rather than a routine succession or promotion.

On July 31, 2026, the Company issued the Milestone Shares to Statera and Avenue, each of which has prior hereto represented that it was an “accredited investor,” as defined in Regulation D. Such issuances were exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in reliance in Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder. 3 Neither the shares of Series A Preferred Stock or the shares of common stock iss…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On July 31, 2026, the Company issued an aggregate of 1,287.8685 shares of Series A Preferred Stock (“Milestone Shares”), as consideration for the Milestone Payment (as discussed in more detail in

2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VALION BIO, INC. Date: June 18, 2026 By: /s/ Melinda Lackey Name: Melinda Lackey Title: General Counsel and Senior Vice President of Legal Affairs 3

The filing pertains to an amendment of the equity incentive plan, not a management change.

Results of Operations and Financial Condition. The information provided below in “

General Counsel and Senior Vice President of Legal Affairs — Melinda Lackey: Ms. Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs.

Results of Operations and Financial Condition. The information provided below in “

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 19, 2026, Tivic Health Systems, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for at least 30 consecutive business days, the Company is not currently in compliance with the m…

Entry into a Material Definitive Agreement. Microbial Building Lease On March 13, 2026, Tivic Health Systems, Inc.’s (the “Company”) wholly owned subsidiary Velocity Bioworks, Inc. (“VBI”) entered into a Building Lease Agreement (the “Microbial Building Lease”) with TPB Merchants Ice LLC (“TPB”) to lease an approximately 8,024 square foot facility (the “Microbial Building”) located at 1305 E. Houston St., San Antonio, TX 78205 (the “Property”). The initial term of the Microbial Building Lease…

CEO — Jennifer Ernst: Jennifer Ernst resigned from her positions as Chief Executive Officer and Board Member.

Entry into a Material Definitive Agreement. Equity Line of Credit Common Stock Purchase Agreement On February 6, 2026, Tivic Health Systems, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Tumim Stone Capital, LLC, a Delaware limited liability company (the “Investor”). Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to sell to the Investor up to the lesser of: (a) $50,000,000 of newly issued shares of t…